205 related articles for article (PubMed ID: 30547371)
1. Understanding Patient Preferences and Unmet Needs in Non-alcoholic Steatohepatitis (NASH): Insights from a Qualitative Online Bulletin Board Study.
Cook NS; Nagar SH; Jain A; Balp MM; Mayländer M; Weiss O; Chatterjee S
Adv Ther; 2019 Feb; 36(2):478-491. PubMed ID: 30547371
[TBL] [Abstract][Full Text] [Related]
2. Patient Needs, Perceptions, and Attitudinal Drivers Associated with Obesity: A Qualitative Online Bulletin Board Study.
Cook NS; Tripathi P; Weiss O; Walda S; George AT; Bushell A
Adv Ther; 2019 Apr; 36(4):842-857. PubMed ID: 30859499
[TBL] [Abstract][Full Text] [Related]
3. Identification of Patient Needs and Preferences in Pigmented Villonodular Synovitis (PVNS) Using a Qualitative Online Bulletin Board Study.
Cook NS; Landskroner K; Shah B; Walda S; Weiss O; Pallapotu V
Adv Ther; 2020 Jun; 37(6):2813-2828. PubMed ID: 32394210
[TBL] [Abstract][Full Text] [Related]
4. Understanding the impact of non-alcoholic steatohepatitis with metabolic comorbidities on adults: a real-world qualitative study.
Shinde S; Taylor N; Chinthammit C; Wilson R; Burgess SM; Poon JL
Curr Med Res Opin; 2024 Apr; 40(4):665-676. PubMed ID: 38363353
[TBL] [Abstract][Full Text] [Related]
5. Gathering Structured Patient Insight to Drive the PRO Strategy in COPD: Patient-Centric Drug Development from Theory to Practice.
Patalano F; Gutzwiller FS; Shah B; Kumari C; Cook NS
Adv Ther; 2020 Jan; 37(1):17-26. PubMed ID: 31707715
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey.
Nadolsky K; Cryer DR; Articolo A; Fisher T; Schneider J; Rinella M
Ann Med; 2023 Dec; 55(1):2211349. PubMed ID: 37171239
[TBL] [Abstract][Full Text] [Related]
7. A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH).
Povsic M; Wong OY; Perry R; Bottomley J
Adv Ther; 2019 Jul; 36(7):1574-1594. PubMed ID: 31065991
[TBL] [Abstract][Full Text] [Related]
8. Assessing physician preferences on future therapeutic options and diagnostic practices in non-alcoholic steatohepatitis.
Cook N; Geier A; Schmid A; Hirschfield G; Kautz A; Schattenberg JM; Balp MM
JHEP Rep; 2020 Apr; 2(2):100081. PubMed ID: 32190823
[TBL] [Abstract][Full Text] [Related]
9. Advanced fibrosis associated with non-alcoholic steatohepatitis (NASH) in Spain: results of a Delphi study.
Aller R; Calleja JL; Crespo J; Romero-Gómez M; Turnes J; Benmarzouk-Hidalgo OJ; Subirán R; Gil A
Gastroenterol Hepatol; 2024 Apr; 47(4):337-346. PubMed ID: 37343722
[TBL] [Abstract][Full Text] [Related]
10. A qualitative patient interview study to understand the experience of patients with nonalcoholic steatohepatitis.
Swain MG; Pettersson B; Meyers O; Venerus M; Oscarsson J
Hepatol Commun; 2023 Mar; 7(3):e0036. PubMed ID: 36757391
[TBL] [Abstract][Full Text] [Related]
11. Current and future treatment options in non-alcoholic steatohepatitis (NASH).
Lazaridis N; Tsochatzis E
Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):357-369. PubMed ID: 28276821
[TBL] [Abstract][Full Text] [Related]
12. Therapies in non-alcoholic steatohepatitis (NASH).
Oseini AM; Sanyal AJ
Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
[TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic Steatohepatitis: A Review.
Sheka AC; Adeyi O; Thompson J; Hameed B; Crawford PA; Ikramuddin S
JAMA; 2020 Mar; 323(12):1175-1183. PubMed ID: 32207804
[TBL] [Abstract][Full Text] [Related]
14. What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?
Alkhouri N; Tincopa M; Loomba R; Harrison SA
Hepatol Commun; 2021 Nov; 5(11):1810-1823. PubMed ID: 34499435
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
Jayakumar S; Middleton MS; Lawitz EJ; Mantry PS; Caldwell SH; Arnold H; Mae Diehl A; Ghalib R; Elkhashab M; Abdelmalek MF; Kowdley KV; Stephen Djedjos C; Xu R; Han L; Mani Subramanian G; Myers RP; Goodman ZD; Afdhal NH; Charlton MR; Sirlin CB; Loomba R
J Hepatol; 2019 Jan; 70(1):133-141. PubMed ID: 30291868
[TBL] [Abstract][Full Text] [Related]
16. Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD).
Tasneem AA; Luck NH; Majid Z
Trop Doct; 2018 Apr; 48(2):107-112. PubMed ID: 29145775
[TBL] [Abstract][Full Text] [Related]
17. Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis.
Traussnigg S; Kienbacher C; Gajdošík M; Valkovič L; Halilbasic E; Stift J; Rechling C; Hofer H; Steindl-Munda P; Ferenci P; Wrba F; Trattnig S; Krššák M; Trauner M
Liver Int; 2017 Oct; 37(10):1544-1553. PubMed ID: 28544208
[TBL] [Abstract][Full Text] [Related]
18. Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study.
Doward LC; Balp MM; Twiss J; Slota C; Cryer D; Brass CA; Anstee QM; Sanyal AJ
Patient; 2021 Sep; 14(5):533-543. PubMed ID: 33336323
[TBL] [Abstract][Full Text] [Related]
19. Clinical practice gaps and challenges in non-alcoholic steatohepatitis care: An international physician needs assessment.
Lazure P; Tomlinson JW; Kowdley KV; Magni P; Santos RD; Jacobs G; Murray S
Liver Int; 2022 Aug; 42(8):1772-1782. PubMed ID: 35635757
[TBL] [Abstract][Full Text] [Related]
20. The Patient Perspectives on Future Therapeutic Options in NASH and Patient Needs.
Cook N; Geier A; Schmid A; Hirschfield G; Kautz A; Schattenberg JM; Balp MM
Front Med (Lausanne); 2019; 6():61. PubMed ID: 31106203
[No Abstract] [Full Text] [Related]
[Next] [New Search]
